Daphna Yael Spiegel, M.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Rectal Neoplasms | 3 | 2020 | 1183 | 1.030 |
Why?
|
| Veterans Health | 2 | 2019 | 216 | 0.710 |
Why?
|
| Radiation Oncology | 3 | 2023 | 568 | 0.630 |
Why?
|
| Lymph Node Excision | 2 | 2023 | 1262 | 0.580 |
Why?
|
| United States Department of Veterans Affairs | 2 | 2020 | 937 | 0.570 |
Why?
|
| Nomograms | 1 | 2018 | 235 | 0.540 |
Why?
|
| Carcinoma, Intraductal, Noninfiltrating | 2 | 2023 | 921 | 0.470 |
Why?
|
| Brachytherapy | 2 | 2018 | 1218 | 0.450 |
Why?
|
| Neoadjuvant Therapy | 3 | 2020 | 2897 | 0.380 |
Why?
|
| Androgen Antagonists | 1 | 2018 | 1411 | 0.330 |
Why?
|
| Patient Protection and Affordable Care Act | 1 | 2018 | 1188 | 0.310 |
Why?
|
| Calcinosis | 1 | 2017 | 1475 | 0.310 |
Why?
|
| Testosterone | 1 | 2018 | 2495 | 0.290 |
Why?
|
| Insurance Coverage | 1 | 2018 | 1945 | 0.280 |
Why?
|
| Stomach Neoplasms | 1 | 2017 | 1471 | 0.270 |
Why?
|
| Adenocarcinoma | 3 | 2018 | 6361 | 0.230 |
Why?
|
| Rectum | 2 | 2020 | 896 | 0.230 |
Why?
|
| Prostatic Neoplasms | 5 | 2018 | 11092 | 0.230 |
Why?
|
| Axilla | 2 | 2023 | 619 | 0.220 |
Why?
|
| Breast Neoplasms | 5 | 2023 | 21072 | 0.190 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 2 | 2020 | 11859 | 0.190 |
Why?
|
| Chemotherapy, Adjuvant | 3 | 2020 | 3546 | 0.180 |
Why?
|
| Disease-Free Survival | 3 | 2020 | 6840 | 0.170 |
Why?
|
| Kaplan-Meier Estimate | 3 | 2020 | 6506 | 0.160 |
Why?
|
| Neoplasms | 2 | 2018 | 22336 | 0.160 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2017 | 9378 | 0.160 |
Why?
|
| Fiber Optic Technology | 1 | 2020 | 290 | 0.150 |
Why?
|
| Radiosurgery | 2 | 2018 | 1328 | 0.140 |
Why?
|
| Mammography | 2 | 2018 | 2423 | 0.140 |
Why?
|
| Lymphedema | 1 | 2023 | 525 | 0.130 |
Why?
|
| Hospitals, Veterans | 1 | 2019 | 395 | 0.130 |
Why?
|
| Clinical Trials, Phase II as Topic | 1 | 2018 | 637 | 0.130 |
Why?
|
| Laryngoscopy | 1 | 2020 | 714 | 0.120 |
Why?
|
| Small Cell Lung Carcinoma | 1 | 2019 | 453 | 0.110 |
Why?
|
| Breast | 2 | 2023 | 1950 | 0.110 |
Why?
|
| Medically Uninsured | 1 | 2018 | 838 | 0.100 |
Why?
|
| Genital Neoplasms, Female | 1 | 2018 | 534 | 0.100 |
Why?
|
| Neoplasm Staging | 5 | 2020 | 11202 | 0.100 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 2017 | 1777 | 0.100 |
Why?
|
| Lymph Nodes | 1 | 2023 | 3457 | 0.090 |
Why?
|
| Radiotherapy, Conformal | 2 | 2014 | 533 | 0.090 |
Why?
|
| Middle Aged | 11 | 2020 | 223035 | 0.090 |
Why?
|
| Uterine Neoplasms | 1 | 2018 | 1425 | 0.080 |
Why?
|
| Carcinoma, Ductal | 1 | 2010 | 97 | 0.080 |
Why?
|
| Aged | 10 | 2020 | 171170 | 0.080 |
Why?
|
| Humans | 19 | 2023 | 766019 | 0.080 |
Why?
|
| United States | 5 | 2023 | 72918 | 0.080 |
Why?
|
| Urologic Surgical Procedures | 1 | 2011 | 281 | 0.080 |
Why?
|
| Proportional Hazards Models | 3 | 2019 | 12529 | 0.080 |
Why?
|
| Mastectomy | 1 | 2017 | 1848 | 0.080 |
Why?
|
| Survivors | 1 | 2018 | 2375 | 0.070 |
Why?
|
| Cystectomy | 1 | 2011 | 603 | 0.070 |
Why?
|
| Multivariate Analysis | 2 | 2018 | 12061 | 0.070 |
Why?
|
| Hospitals, General | 1 | 2011 | 803 | 0.070 |
Why?
|
| Combined Modality Therapy | 1 | 2018 | 8524 | 0.070 |
Why?
|
| Neoplasm Metastasis | 1 | 2017 | 4886 | 0.070 |
Why?
|
| Uterine Cervical Neoplasms | 1 | 2018 | 2039 | 0.070 |
Why?
|
| Pituitary Neoplasms | 1 | 2014 | 1322 | 0.060 |
Why?
|
| Patient Care Team | 1 | 2017 | 2517 | 0.060 |
Why?
|
| Head and Neck Neoplasms | 1 | 2020 | 2926 | 0.060 |
Why?
|
| Medicaid | 1 | 2018 | 2835 | 0.060 |
Why?
|
| Female | 11 | 2023 | 396174 | 0.060 |
Why?
|
| Clinical Trials as Topic | 2 | 2018 | 8037 | 0.060 |
Why?
|
| Male | 10 | 2020 | 363880 | 0.060 |
Why?
|
| Adenoma | 1 | 2014 | 2155 | 0.050 |
Why?
|
| Aged, 80 and over | 6 | 2019 | 59497 | 0.050 |
Why?
|
| Positron-Emission Tomography | 1 | 2019 | 6545 | 0.050 |
Why?
|
| Registries | 1 | 2018 | 8343 | 0.050 |
Why?
|
| Internship and Residency | 1 | 2020 | 5946 | 0.040 |
Why?
|
| Urinary Bladder Neoplasms | 1 | 2011 | 2184 | 0.040 |
Why?
|
| Sentinel Lymph Node Biopsy | 1 | 2023 | 733 | 0.040 |
Why?
|
| Prospective Studies | 1 | 2023 | 54804 | 0.040 |
Why?
|
| Treatment Outcome | 4 | 2018 | 65203 | 0.040 |
Why?
|
| Quality of Life | 1 | 2018 | 13464 | 0.030 |
Why?
|
| Adult | 4 | 2018 | 223110 | 0.030 |
Why?
|
| Radiotherapy Dosage | 2 | 2014 | 2863 | 0.030 |
Why?
|
| Reactive Oxygen Species | 1 | 2023 | 2144 | 0.030 |
Why?
|
| Young Adult | 2 | 2018 | 59858 | 0.030 |
Why?
|
| Lung Neoplasms | 1 | 2019 | 13483 | 0.030 |
Why?
|
| Necrosis | 1 | 2018 | 1614 | 0.030 |
Why?
|
| Hypopituitarism | 1 | 2014 | 253 | 0.020 |
Why?
|
| Acromegaly | 1 | 2014 | 316 | 0.020 |
Why?
|
| Thyrotropin | 1 | 2014 | 834 | 0.020 |
Why?
|
| Feasibility Studies | 1 | 2020 | 5301 | 0.020 |
Why?
|
| Students, Medical | 1 | 2020 | 1961 | 0.020 |
Why?
|
| Odds Ratio | 1 | 2019 | 9655 | 0.020 |
Why?
|
| Health Expenditures | 1 | 2018 | 2389 | 0.020 |
Why?
|
| Follow-Up Studies | 2 | 2018 | 39233 | 0.010 |
Why?
|
| Comorbidity | 1 | 2019 | 10577 | 0.010 |
Why?
|
| Neoplasm Invasiveness | 1 | 2011 | 3604 | 0.010 |
Why?
|
| Pandemics | 1 | 2023 | 8724 | 0.010 |
Why?
|
| Medicare | 1 | 2018 | 6820 | 0.010 |
Why?
|
| Boston | 1 | 2011 | 9335 | 0.010 |
Why?
|
| Retrospective Studies | 2 | 2018 | 81544 | 0.010 |
Why?
|
| Risk Assessment | 1 | 2011 | 24272 | 0.010 |
Why?
|
| Time Factors | 1 | 2011 | 40100 | 0.010 |
Why?
|
| Child | 1 | 2014 | 80567 | 0.000 |
Why?
|
| Adolescent | 1 | 2014 | 88808 | 0.000 |
Why?
|
| Risk Factors | 1 | 2011 | 74837 | 0.000 |
Why?
|